礼来公司宣布收购Organovo旗下的FXR项目及其主打疗法FXR314，这是一款用于治疗溃疡性结肠炎等疾病的潜在“best-in-class”口服FXR小分子激动剂。Organovo已获得美国FDA的临床试验许可，正在进行2期试验，并计划将其应用于 ...

Eli Lilly (Lilly) has agreed to make a $10m upfront payment for full worldwide rights to San Diego-based Organovo Holdings’ ...

Onvo Stock- Organovo's stock jumps 200% after Eli Lilly acquires its FXR program, including the promising IBD treatment ...

Eli Lilly has acquired Organovo’s lead asset, a clinical FXR agonist designed to treat inflammatory bowel disease (IBD), in a ...

The deal with Lilly is a crucial boost for Organovo, which ended last year with just $1.2 million in cash and nearly $350 million in debt. Organovo FXR is a clinical drug program focused on farnesoid ...

周二，礼来公司（Eli Lilly, NYSE: ...

全球制药巨头礼来近日宣布以4.5亿美元收购Organovo的FXR项目，这项交易不仅创下2025年开年最大生物技术并购案，更折射出药物研发领域正在经历范式转移。在传统新药研发成功率持续低迷的背景下（2024年Nature数据显示临床阶段药物失败率仍高达85%），Organovo凭借其革命性的3D生物打印技术平台，成功推动FXR314在溃疡性结肠炎等适应症上展现出best-in-class潜力。这场 ...

智通财经APP获悉，Organovo Holdings今日宣布，礼来(LLY.US)（Eli Lilly and Company）将收购该公司旗下的FXR项目及主打疗法FXR314。FXR314是一款潜在“best-in-class”的口服FXR小分子激动剂。目前，Organovo已获得美国FDA的临床试验许可，正在进行其主打疗法FXR314用于治疗溃疡性结肠炎（UC）的2期试验。 公司通过其专有 ...

FXR314是一款潜在“best-in-class”的口服FXR小分子激动剂。目前，Organovo已获得美国FDA的临床试验许可，正在进行其主打疗法FXR314用于治疗溃疡性结肠炎（UC）的2期试验。公司通过其专有的3D人体组织模型，制定了针对FX ...

Organovo today announced that Eli Lilly and Company (NYSE:LLY) ("Lilly") will acquire Organovo's FXR program, including its ...

A California-based biotech company is finding a tremendous amount of success on Tuesday after the company announced that Eli ...

US pharma major Eli Lilly has announced a deal with San Diego-based Organovo Holdings, a biotech focused on developing novel ...